{"id":"NCT03764618","sponsor":"Rigel Pharmaceuticals","briefTitle":"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-24","primaryCompletion":"2022-04-11","completion":"2022-04-11","firstPosted":"2018-12-05","resultsPosted":"2023-05-25","lastUpdate":"2023-05-25"},"enrollment":90,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Warm Antibody Autoimmune Hemolytic Anemia"],"interventions":[{"type":"DRUG","name":"Fostamatinib disodium","otherNames":["R935788","Fostamatinib"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Fostamatinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).","primaryOutcome":{"measure":"Durable Hemoglobin Response","timeFrame":"24 Weeks","effectByArm":[{"arm":"Fostamatinib","deltaMin":16,"sd":null},{"arm":"Placebo","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":102,"countries":["United States","Australia","Austria","Belarus","Belgium","Bulgaria","Canada","Czechia","Denmark","France","Georgia","Germany","Hungary","Italy","Netherlands","Norway","Romania","Russia","Serbia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":45},"commonTop":["Warm type hemolytic anemia","Hypertension","Diarrhea","Hemoglobin decreased","Fatigue"]}}